Back to Search
Start Over
Health-state utilities in long-term advanced melanoma survivors comparable with the general population
- Source :
- Egeler, M D, van de Poll-Franse, L V, Tissier, R, Rogiers, A, Boers-Sonderen, M J, van den Eertwegh, A J, Hospers, G A, de Groot, J W B, Aarts, M J B, Kapiteijn, E, Piersma, D, Vreugdenhil, G, van der Veldt, A A, Suijkerbuijk, K P M, Neyns, B, Janssen, K J, Blank, C U, Retèl, V P & Boekhout, A H 2023, ' Health-state utilities in long-term advanced melanoma survivors comparable with the general population ', Quality of Life Research . https://doi.org/10.1007/s11136-023-03427-9, Quality of Life Research. Springer Netherlands
- Publication Year :
- 2023
-
Abstract
- BACKGROUND: Checkpoint inhibitors have been shown to substantially improve the survival of patients with advanced melanoma. With this growing group of survivors treated with immunotherapies, assessing their health-state utilities is essential and can be used for the calculation of quality-adjusted life years and for cost-effectiveness analyses. Therefore, we evaluated the health-state utilities in long-term advanced melanoma survivors.METHODS: Health-state utilities were evaluated in a cohort of advanced melanoma survivors 24-36 months (N = 37) and 36-plus months (N = 47) post-ipilimumab monotherapy. In addition, the health-state utilities of the 24-36 months survivor group were assessed longitudinally, and utilities of the combined survival groups (N = 84) were compared with a matched control population (N = 168). The EQ-5D was used to generate health-state utility values, and quality-of-life questionnaires were used to establish correlations and influencing factors of utility scores.RESULTS: Health-state utility scores were similar between the 24-36 months'- and the 36-plus months' survival group (0.81 vs 0.86; p = .22). In survivors, lower utility scores were associated with symptoms of depression (β = - .82, p = .022) and fatigue burden (β = - .29, p = .007). Utility scores did not significantly change after 24-36 months of survival, and the utilities of survivors were comparable to the matched control population (0.84 vs 0.87; p = .07).DISCUSSION: Our results show that long-term advanced melanoma survivors treated with ipilimumab monotherapy experience relatively stable and high health-state utility scores.
Details
- Language :
- English
- ISSN :
- 09629343
- Database :
- OpenAIRE
- Journal :
- Egeler, M D, van de Poll-Franse, L V, Tissier, R, Rogiers, A, Boers-Sonderen, M J, van den Eertwegh, A J, Hospers, G A, de Groot, J W B, Aarts, M J B, Kapiteijn, E, Piersma, D, Vreugdenhil, G, van der Veldt, A A, Suijkerbuijk, K P M, Neyns, B, Janssen, K J, Blank, C U, Retèl, V P & Boekhout, A H 2023, ' Health-state utilities in long-term advanced melanoma survivors comparable with the general population ', Quality of Life Research . https://doi.org/10.1007/s11136-023-03427-9, Quality of Life Research. Springer Netherlands
- Accession number :
- edsair.doi.dedup.....999af54e77227da50ad3b68c8c160444